NHAS
ADAP

Novo Holdings A/S’s Adaptimmune Therapeutics ADAP Stock Holding History

Novo Holdings A/S’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,411,567
Closed -$16.9M – 15
2015
Q3 		$16.9M Sell
1,411,567
-350,000
-20% -$4.94M 1.75% 8
2015
Q2 		$32.3M Buy
+1,761,567
New +$30.2M 2.32% 10

Other funds holding ADAP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Novo Holdings A/S's ADAP Position: Q4 2015 in Review

Novo Holdings A/S sold out of Adaptimmune Therapeutics (ADAP) in Q4 2015, closing a stake of 1,411,567 shares — an estimated $16.9M sold.

Novo Holdings A/S first reported a position in ADAP in Q2 2015 and held it in 2 quarters. The position peaked at $32.3M in Q2 2015. 49 funds tracked by Wall St. Rank hold ADAP as of Q4 2015.

  • Novo Holdings A/S reported no remaining Adaptimmune Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Novo Holdings A/S sold 1,411,567 Adaptimmune Therapeutics shares in Q4 2015, an estimated $16.9M.
  • Novo Holdings A/S first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 2 quarters.
  • Novo Holdings A/S's Adaptimmune Therapeutics position peaked at $32.3M in Q2 2015.
  • 49 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2015.

Based on Novo Holdings A/S's 13F filing for Q4 2015, filed 16 Feb 2016.